Harmonigenic™ Corporation was founded to guide from the lab to the clinic, a University of Rochester discovery that if validated will provide better outcomes for cancer patients including better quality of life and lower overall cost by directing earlier treatment for those who have not clinically progressed to Stage IV but are are at high risk for recurrence as Stage IV metastatic cancer.
Who we help
We are dedicated improving the accuracy of metastatic cancer diagnosis with better treatment decisions that provide better outcomes for cancer patients including better quality of life.
We are developing an assay of collagen in cancer tissue called OPTIM (Optical Prediction of Time Interval to Metastasis). OPTIM predicts which cancers have already metastasized to distant sites and should receive early targeted treatment if avaialble and which have a much lower risk of recurrence.